Search clinical trials for: Aclidinium bromide 400 μg bid

Total 476 results

AstraZeneca

Completed

Efficacy and Safety of Aclidinium Bromide at Two Dose Levels Versus Placebo Administered in Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease (COPD)

Germany, Czech Republic, France, Hungary, Italy, Peru, Poland, Russian Federation, South Africa, Spain, Ukraine
Daewoong Pharmaceutical Co. LTD.

Completed

Efficacy and Safety of 400 μg Twice Daily of Aclidinium Bromide vs. Placebo When Administered to Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

COPD

Korea, Republic of
AstraZeneca

Completed

Efficacy and Safety of Three Doses of Aclidinium Bromide Compared to Placebo and to an Active Comparator in Chronic Obstructive Pulmonary Disease (COPD) Patients.

Chronic Obstructive Pulmonary Disease (COPD)

Belgium, Germany
AstraZeneca

Completed

A Phase I, Open-Label, Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide in Healthy Chinese Participants

Healthy Volunteers

China
AstraZeneca

Completed

Long-term Safety, Tolerability and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-35) (LAS-MD-35)

Chronic Obstructive Pulmonary Disease

United States, Canada
AstraZeneca

Completed

Efficacy of Aclidinium Bromide Administered in Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease (COPD)

Germany
AstraZeneca

Completed

AMPLIFY - D6571C00001 Duaklir USA Phase III Study

Chronic Obstructive Pulmonary Disease

United States, Germany, Poland, Israel, Bulgaria, Czechia, Hungary, Spain, Ukraine, United Kingdom
AstraZeneca

Completed

Efficacy and Safety of Aclidinium Bromide for Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-33)

Chronic Obstructive Pulmonary Disease

United States, Canada
AstraZeneca

Completed

Long-term Extension Study of the Safety, Tolerability, and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-36)

Chronic Obstructive Pulmonary Disease

United States, Canada
AstraZeneca

Completed

Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients. (ASCENT COPD)

Chronic Obstructive Pulmonary Disease | COPD | Moderate to Very Severe COPD

United States, Canada
AstraZeneca

Completed

Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38) (LAS-MD-38)

Chronic Obstructive Pulmonary Disease

United States, Canada
AstraZeneca

Completed

A Trial Assessing LAS34273 in Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

Andorra, Austria, Belgium, Bulgaria, Czech Republic, Denmark, France, Germany, Hungary, Italy, Netherlands, Poland, Romania, Russian Federation, Spain, United Kingdom
AstraZeneca

Completed

Efficacy and Safety of Aclidinium Bromide 400 µg BID (Twice a Day)Compared to Placebo in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

Germany, Spain, United Kingdom
AstraZeneca
Menarini Group

Completed

BENEFITS OF ACLIDINIUM BROMIDE IN THE RELIEF OF COPD SYMPTOMS INCLUDING COUGH (M-34273-46)

Pulmonary Disease, Chronic Obstructive

Italy, Spain, United Kingdom, Germany, Hungary
AstraZeneca

Completed

A Study of Exercise Endurance and Lung Hyperinflation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Canada
AstraZeneca

Completed

Efficacy and Safety of LAS 34273 in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease(COPD)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Argentina, Australia, Canada, Mexico, New Zealand, South Africa
AstraZeneca

Completed

A Double-blind, Placebo-controlled, Crossover Study to Assess the Effect of Aclidinium Bromide 400 μg Bid on COPD Symptoms and Sleep Quality After 3 Weeks of Treatment in Patients With Stable Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

Germany
AstraZeneca

Completed

Efficacy and Safety Study of Two Fixed-dose Combinations of Aclidinium Bromide With Formoterol Fumarate Compared With Aclidinium Bromide, Formoterol Fumarate and Placebo (LAC-MD-27)

Chronic Obstructive Pulmonary Disease

United States
AstraZeneca

Completed

Efficacy and Safety of Two Fixed Dose Combinations of Aclidinium Bromide With Formoterol Fumarate (ALIGHT-COPD)

Chronic Obstructive Pulmonary Disease

Romania, Czech Republic
Rennes University Hospital

Completed

Fludrocortisone in Healthy Volunteers (AFLUCO4) (AFLUCO4)

Healthy Volunteers

France
Innovation Pharmaceuticals, Inc.

Completed

Efficacy and Safety of Prurisol Administered Orally for Active Moderate to Severe Chronic Plaque Psoriasis

Chronic Stable Plaque Psoriasis

United States
Alebund Pty Ltd

Completed

A Safety, Tolerability, and Pharmacokinetics Study of AP303 in Healthy Subjects

Healthy Subjects

Australia
AstraZeneca

Completed

Safety and Tolerability Study of MEDI0382 in Japanese Preobese or Obese Subjects With Type 2 Diabetes

Type 2 Diabetes

Japan
Judit Pich Martínez

Completed

A Phase I, Open Label Dose Escalation Study to Evaluate Safety of iHIVARNA-01 in Chronically HIV-infected Patients Under Stable Combined Antiretroviral Therapy

HIV-infection

Spain
AstraZeneca
RTI Health Solutions

Recruiting

Aclidinium Bromide Post-Authorisation Safety Study to Evaluate the Risk of Cardiovascular Endpoints (PASS)

Pulmonary Disease, Chronic Obstructive

United Kingdom
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

First in Human Study of M4344 in Participants With Advanced Solid Tumors

Solid Tumor | Advanced Solid Tumor

Spain, United States, Netherlands, United Kingdom
AstraZeneca

Completed

Pharmacokinetics, Safety and Tolerability of Twice-Daily Aclidinium Bromide/Formoterol Fumarate Fixed Dose Combination in Chinese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

China
Hamamatsu University

Completed

Comparison of Vonoprazan-based Dual and Triple Therapies for H. Pylori Eradication

Gastritis Associated With Helicobacter Pylori

Japan
GlaxoSmithKline

Completed

Safety and Immunogenicity Study of a Booster Dose of the Investigational CV0501 mRNA COVID-19 Vaccine in Adults at Least 18 Years Old

COVID-19 | SARS-CoV-2

Australia, United States, Philippines
Hoffmann-La Roche

Completed

Safety, Tolerability, and Antiviral Activity of ANA598 in Patients With Genotype-1 Chronic HCV Infection

Chronic Hepatitis C

United States, Puerto Rico
Dr. Reddy's Laboratories Limited
XenoPort, Inc.

Completed

A Study to Assess the Efficacy and Safety of XP23829 in Subjects With Moderate-to-Severe Chronic Plaque-Type Psoriasis

Psoriasis

United States
Botanix Pharmaceuticals

Completed

A Safety Study of BBI-4000 Gel in Patients With Axillary Hyperhidrosis

Primary Axillary Hyperhidrosis

United States
AstraZeneca

Recruiting

A 12-week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants With Inadequately Controlled Asthma (LITHOS) (LITHOS)

Asthma

United States, Canada, South Africa, Korea, Republic of, Philippines, Czechia, Malaysia, Germany
Alebund Pharmaceuticals

Not yet recruiting

A Study to Evaluate the Safety, Tolerability, PK and PD of AP303 in Healthy Chinese Participants

Healthy Subjects
AstraZeneca

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7594 Inhaled Formulation in Healthy Japanese Men

Asthma | Chronic Obstructive Pulmonary Disease COPD

United States
AstraZeneca

Completed

A Study to Assess Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease

Parkinson's Disease

United States
AstraZeneca

Completed

Efficacy, Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United States, Australia, Canada, New Zealand
AstraZeneca

Completed

Long-term Efficacy and Safety of Aclidinium Bromide/Formoterol Fumarate Fixed-Dose Combination

Chronic Obstructive Pulmonary Disease (COPD)

Austria, Belgium, Bulgaria, Croatia, Czech Republic, Denmark, Finland, France, Germany, Hungary, Italy, Korea, Republic of, Netherlands, Poland, Romania, Russian Federation, Slovakia, South Africa, Spain, Sweden, Ukraine, United Kingdom
University of Dundee
AstraZeneca; NHS Tayside

Completed

Microbiome Use to Stratify Use of Inhaled Corticosteroids: MUSIC Trial (MUSIC)

Chronic Obstructive Pulmonary Disease

United Kingdom
Botanix Pharmaceuticals

Completed

A Safety Study of BBI-4000 Gel in Pediatric Patients With Axillary Hyperhidrosis

Primary Axillary Hyperhidrosis

United States
AstraZeneca

Completed

Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United States, Australia, Canada, New Zealand
AstraZeneca

Completed

Aclidinium/Formoterol Fixed Combination Dose Finding Study

Chronic Obstructive Pulmonary Disease (COPD)

Russian Federation, Australia, Czech Republic, Poland
AstraZeneca
Parexel

Completed

Study to Assess Efficacy and Safety of Aclidinium Bromide and Aclidinium Bromide/Formoterol Fumarate in Stabile COPD Patients (AVANT)

COPD

Philippines, Vietnam, China, Taiwan, India
N-Gene Research Laboratories, Inc.
Thermo Fisher Scientific, Inc; Integrium; Msource Medical Development GmbH; Kinexum... and other collaborators

Terminated

Safety and Efficacy of BGP-15 in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus

United States, Germany, Hungary
Altavant Sciences GmbH
Parexel; Altavant Sciences, Inc.

Completed

Multiple-Ascending Dose in Japanese Patients Bridging Study

Healthy

United States
GlaxoSmithKline

Completed

Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of GSK2292767 in Healthy Participants Who Smoke Cigarettes

Asthma

United Kingdom
Altavant Sciences GmbH

Completed

A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension (ELEVATE 2)

Pulmonary Arterial Hypertension

United States, Spain, United Kingdom, Czechia, Serbia, Canada, Poland, Italy, Bosnia and Herzegovina, Austria, Germany, Belgium, Bulgaria, France, Latvia, Moldova, Republic of, Ukraine
Lexicon Pharmaceuticals

Completed

A Study to Determine the Safety and Efficacy of LX3305 in Subjects With Active Rheumatoid Arthritis

Rheumatoid Arthritis

United States
Mylan Pharmaceuticals Inc

Completed

Fasting Study of Levothyroxine Sodium Tablets 300 μg to Synthroid® Tablets 300 μg

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Fasting Study of Levothyroxine Sodium Tablets 300 μg to Levothroid® Tablets 300 μg

Healthy

United States

3

Subscribe